| Drug | Total patent applications | # Patents Issued | % Filed after FDA approval | Duration of patent protection | Patents filed in U.S. vs. Europe | Patents filed in U.S. vs. Japan | % Price increase 2012-2018 |
>5% Medicare annual price increase |
>10% Medicaid annual price increase |
Top 15 Medicare total spending (rank) | Medicare spending per beneficiary | Years on the U.S. market | Generic / biosimilar approved by FDA (year) | Generic / biosimilar on the U.S. market (year) | Company | Condition(s) Treated | Drug Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herceptin | 186 | 108 | 84% | 48 | 2.4x | 1.5x | -58% | - | - | - | $34,000 | 20 | ✔ 2017 | - | Pfizer/BMS | Cancer | Biologic |
| Revlimid | 106 | 96 | 40 | 2.7x | 2.9x | 79% | - | - | ✔ 2 | $75,238 | 13 | - | - | BMS/Celgene | Multiple Myeloma | Small Molecule | |
| Humira | 247 | 132 | 89% | 39 | 3.3x | 3.9x | 144% | ✔ 18% | ✔ 17% | ✔ 14 | $34,024 | 16 | - | - | AbbVie | Arthritis | Biologic |
| Enbrel | 57 | 41 | 72% | 39 | 2.9x | 3.2x | 155% | ✔ 18% | ✔ 18% | ✔ 15 | $32,891 | 20 | ✔ 2016 | - | Amgen | Arthritis | Biologic |
| Rituxan | 204 | 94 | 90% | 47 | 1.8x | 1.8x | 25% | ✔ 6% | - | ✔ 13 | $23,815 | 21 | ✔ 2017 | ✔ 2017 | Biogen/Genentech | Cancer | Biologic |
| Remicade | 123 | 66 | 93% | 32 | 6.1x | 4.4x | 18% | ✔ 6% | - | - | $22,925 | 20 | ✔ 2016 | ✔ 2016 | Johnson&Johnson | Arthritis | Biologic |
| Eylea | 67 | 51 | 37% | 31 | 3.1x | 4.4x | 6% | - | - | ✔ 7 | $10,497 | 7 | - | - | Bayer/Regeneron | Macular Degeneration | Biologic |
| Avastin | 219 | 86 | 73% | 43 | 2.2x | 1.9x | 16% | - | - | - | $5,360 | 14 | ✔ 2017 | ✔ 2017 | Roche | Cancer | Biologic |
| Lyrica | 118 | 68 | 21% | 32 | 1.9x | 1.9x | 163% | ✔ 17% | ✔ 18% | ✔ 8 | $2,462 | 14 | - | - | Pfizer | Pain | Small Molecule |
| Xarelto | 49 | 30 | 39% | 34 | 87% | ✔ 11% | - | ✔ 9 | $2,420 | 7 | - | - | Johnson&Johnson | Blood Clots | Small Molecule | ||
| Lantus | 74 | 49 | 95% | 37 | 1.7x | 3.1x | 114% | ✔ 16% | ✔ 16% | ✔ 3 | $2,349 | 18 | ✔ 2015 | ✔ 2016 | Sanofi | Diabetes | Biologic (insulin) |
| Eliquis | 48 | 27 | 35% | 34 | 2.7x | 2.8x | 69% | - | - | ✔ 10 | $2,329 | 6 | - | - | Pfizer/BMS | Stroke/ Embolism | Small Molecule |
| Average | 124.8 | 70.7 | 66% | 38 | 2.8x | 2.9x | 68% | $20,693 | 14.7 |
Numbers in pink font indicate above the average for the 10 drugs
- Patent data as of August 2018
- Data on pricing changes were obtained from IQVIA monthly NSP prices from June 2012 to May, 2018 These represent total spending on prescription medicines from wholesaler transactions and include all on-invoice discounts, but no off-invoice discounts or rebates
- Data on prices and spending for Medicare and Medicaid were obtained from the CMS ‘Drug Spending Database’ and reflect data from 2012-2016
- Medicare price increases are based on average annual changes in the price per beneficiary over the period 2012-2016 and spending per beneficiary is for 2016
- Medicaid price increases are based on average changes in the spending per dosage unit over the period 2012-2016
- Humira and Humira Pen are combined and reflect the total for Medicare and Medicaid spending rank; annual price increases reflect the average of the two product sub-types